Literature DB >> 18388801

The role of B cells in multiple sclerosis: rationale for B-cell-targeted therapies.

Michael K Racke1.   

Abstract

Multiple sclerosis is an inflammatory demyelinating disease of the central nervous system with no clear etiology. Until recently, most studies have emphasized the role of T cells in the pathogenesis of multiple sclerosis. Data suggesting that B cells play a role in the pathogenesis of multiple sclerosis have been accumulating for the past five decades, demonstrating that the cerebrospinal fluid and central nervous system tissues of multiple sclerosis patients contain B cells, plasma cells, antibodies, and immunoglobulins. Data suggest that B cells are involved in antigen capture and presentation to T cells, cytokine production, antibody secretion, demyelination, tissue damage, and remyelination in multiple sclerosis. These advances in the understanding of B-cell and antibody roles in the pathophysiology of multiple sclerosis provide a strong rationale for B-cell-targeted therapies.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18388801     DOI: 10.1097/01.wco.0000313359.61176.15

Source DB:  PubMed          Journal:  Curr Opin Neurol        ISSN: 1350-7540            Impact factor:   5.710


  16 in total

Review 1.  Development of anti-CD20 therapy for multiple sclerosis.

Authors:  Beatrix Bartok; Gregg J Silverman
Journal:  Exp Cell Res       Date:  2011-04-12       Impact factor: 3.905

2.  Chemotherapeutics in the treatment of multiple sclerosis.

Authors:  Bernd C Kieseier; Douglas R Jeffery
Journal:  Ther Adv Neurol Disord       Date:  2010-09       Impact factor: 6.570

3.  Identifying patient subtypes in multiple sclerosis and tailoring immunotherapy: challenges for the future.

Authors:  Philip L De Jager
Journal:  Ther Adv Neurol Disord       Date:  2009-11       Impact factor: 6.570

4.  A small-molecule inhibitor of macrophage migration inhibitory factor for the treatment of inflammatory disease.

Authors:  Aaron P Kithcart; Gina M Cox; Thais Sielecki; Abigail Short; James Pruitt; Tracey Papenfuss; Todd Shawler; Ingrid Gienapp; Abhay R Satoskar; Caroline C Whitacre
Journal:  FASEB J       Date:  2010-07-12       Impact factor: 5.191

5.  Analysis of antibodies to surface epitopes of contactin-2 in multiple sclerosis.

Authors:  Anna Boronat; María Sepúlveda; Sara Llufriu; Lidia Sabater; Yolanda Blanco; Iñigo Gabilondo; Nuria Solà; Pablo Villoslada; Josep Dalmau; Francesc Graus; Albert Saiz
Journal:  J Neuroimmunol       Date:  2012-01-14       Impact factor: 3.478

6.  MMP-9 expression is increased in B lymphocytes during multiple sclerosis exacerbation and is regulated by microRNA-320a.

Authors:  Latt Latt Aung; M Maral Mouradian; Suhayl Dhib-Jalbut; Konstantin E Balashov
Journal:  J Neuroimmunol       Date:  2014-11-10       Impact factor: 3.478

Review 7.  Complement in multiple sclerosis: its role in disease and potential as a biomarker.

Authors:  G Ingram; S Hakobyan; N P Robertson; B P Morgan
Journal:  Clin Exp Immunol       Date:  2008-11-24       Impact factor: 4.330

8.  Autoantibodies to Non-myelin Antigens as Contributors to the Pathogenesis of Multiple Sclerosis.

Authors:  Michael C Levin; Sangmin Lee; Lidia A Gardner; Yoojin Shin; Joshua N Douglas; Chelsea Cooper
Journal:  J Clin Cell Immunol       Date:  2013-06-30

Review 9.  Development of oral cladribine for the treatment of multiple sclerosis.

Authors:  Hans-Peter Hartung; Orhan Aktas; Bernd Kieseier; Giancarlo Comi Giancarlo Comi
Journal:  J Neurol       Date:  2010-02       Impact factor: 4.849

Review 10.  Altered expression of microRNAs and B lymphocytes during Natalizumab therapy in multiple sclerosis.

Authors:  André Eduardo de Almeida Franzoi; Fernanda Subtil de Moraes Machado; Washigton Luiz Gomes de Medeiros Junior; Isabelle Pastor Bandeira; Wesley Nogueira Brandão; Marcus Vinicius Magno Gonçalves
Journal:  Heliyon       Date:  2021-06-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.